← All trials
NCT05618327
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2022
- Primary completion
- Dec 24, 2024
- Completion date
- Feb 22, 2025
- First posted
- Nov 16, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 219
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Junshi Bioscience Co.,Ltd.Lead sponsor
- Peking UniversityOverall official - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.